The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Current and future advancements in the treatment of CLL
Stephan Stilgenbauer, MD, from Ulm University, Ulm, Germany, discusses the current advancements in the treatment of chronic lymphocytic leukemia (CLL), including the development of novel agents such as venetoclax and idelalisib, CAR T-cell therapy, immunomodulatory drugs and second-generation BTK inhibitors. He explains that for further advancements to be made, research should be focused on elucidating the biology of the disease, defining subgroups of CLL and identifying more resistance markers that may guide and individualise treatment. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
